In this report we discuss the possibility of using antisense oligonucleotides specific to PAI-1 mRNA to reversibly decrease PAI-1 level in blood plasma and thus prolong a half-life time endogenous plasminogen activators in circulation.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.